跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
東 雅惠
副教授
藥學系
https://orcid.org/0000-0003-0748-7993
電話
02-28267986
電子郵件
ydong3
ym.edu
tw
h-index
h10-index
h5-index
950
引文
16
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
563
引文
14
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
179
引文
8
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2011
2024
每年研究成果
概覽
指紋
網路
研究成果
(45)
類似的個人檔案
(4)
指紋
查看啟用 Yaa-Hui Dong 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Confidence Interval
53%
Hazard Ratio
48%
Chronic Obstructive Pulmonary Disease
36%
Population-based Cohort Study
32%
Inhaled Corticosteroids
23%
Warfarin
23%
Statins
23%
Type 2 Diabetic Patients
22%
Hospitalization
21%
Taiwan
20%
Type 2 Diabetes Mellitus (T2DM)
20%
Fluoroquinolones
20%
Retrospective Cohort Study
19%
Propensity Score Matching
18%
Glucagon-like
15%
A1 Receptor
15%
Receptor Agonist
15%
Systematic Meta-analysis
15%
Selective Serotonin Reuptake Inhibitors
15%
Multi-database
15%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
13%
Pharmacy
13%
Beta-blockers
12%
Claims Database
12%
Long-acting β2-agonist
12%
Meta-analysis
11%
Comparative Safety
11%
Long-acting muscarinic Antagonist
10%
Comorbidity
10%
Fixed-dose Combination
10%
Cardiovascular Safety
10%
Concomitant Use
10%
Medication Adherence
10%
Meta-analysis of Randomized Controlled Trials
10%
Clinical Characteristics
10%
Invasive Breast Cancer
10%
Middle-aged Adults
10%
Elderly Adults
10%
Survival Prognosis
10%
Adult Female
10%
Lifestyle Characteristics
10%
Breast Cancer Patients
10%
5-year Survival
10%
Rhegmatogenous Retinal Detachment
10%
Direct Oral Anticoagulants
10%
Representative Claims
10%
Rifampin
10%
Population-based
9%
Bleeding Events
8%
Incidence Rate
8%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
100%
Chronic Obstructive Lung Disease
55%
Non Insulin Dependent Diabetes Mellitus
30%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
24%
Warfarin
22%
Quinolone Derivative
20%
Comorbidity
19%
Diseases
17%
Statin (Protein)
16%
Selective Serotonin Reuptake Inhibitor
15%
Glucagon Like Peptide 1 Receptor Agonist
15%
Sodium Glucose Cotransporter 2 Inhibitor
13%
Muscarinic Receptor Blocking Agent
11%
Randomized Controlled Trial
10%
Infection
10%
Bronchodilating Agent
10%
Retina Detachment
10%
Direct Oral Anticoagulant
10%
Rifampicin
10%
Brain Ischemia
10%
Congestive Heart Failure
8%
Brain Hemorrhage
8%
Anticoagulant Agent
7%
Heart Infarction
7%
Calcium Channel Blocker
6%
Atrial Fibrillation
6%
Chronic Disease
6%
Antibiotics
6%
Dry Powder Inhaler
5%
Cardiovascular Disease
5%
Sulfonylurea
5%
Case-Control Study
5%
Pharmacoepidemiology
5%
Acarbose
5%
Fibric Acid Derivative
5%
Acute Coronary Syndrome
5%
Clopidogrel
5%
Lung Cancer
5%
Antithrombotic Therapy
5%
Tamoxifen
5%
Cancer Incidence
5%
Liver Injury
5%
Influenza A
5%
Aortic Dissection
5%
Rheumatoid Arthritis
5%
Beclometasone
5%
Aortic Aneurysm
5%
Thiazolidinedione
5%
Abscess
5%
Aortic Regurgitation
5%
Medicine and Dentistry
Cohort Analysis
36%
Hazard Ratio
22%
Patient with Type 2 Diabetes
15%
Chronic Obstructive Pulmonary Disease
15%
Maturity Onset Diabetes of the Young
15%
Glucagon-Like Peptide-1 Agonist
15%
Sodium Glucose Cotransporter 2 Inhibitor
13%
Cardiovascular System
11%
Breast Cancer
11%
Middle Age
10%
Retrospective Cohort Study
7%
Meta-Analysis
6%
Cancer Incidence
5%
Cancer Therapy
5%
Sulfonylurea
5%
Congestive Heart Failure
5%
Diseases
5%
Acarbose
5%
Biological Product
5%
Infection
5%
Roux-en-Y Gastric Bypass
5%
TNF Inhibitor
5%
Cancer in Young Adults
5%
Hepatitis C
5%
Limb
5%
Fragility Fracture
5%
Hepatitis B
5%
Rheumatoid Arthritis
5%
Olmesartan
5%
Liver Cirrhosis
5%
Nutritional Deficiency
5%
Systematic Review
5%
Bronchodilating Agent
5%
Muscarinic Antagonist
5%
Calcium Channel Blocking Agent
5%
Anemia
5%
Selective Serotonin Reuptake Inhibitor
5%
Thiazolidinedione
5%
Nonsteroid Antiinflammatory Agent
5%
Patient with Hypertension
5%
Abscess
5%
Enteropathy
5%
Tamoxifen
5%
Cancer Research
5%
Inflammatory Arthritis
5%
Acute Coronary Syndrome
5%
Radiation Therapy
5%
Proportional Hazards Model
5%
